5 – 6 MARCH 2026
DOUBLETREE BY HILTON LONDON | TOWER OF LONDON | UKImmuno-Mark Summit, 2026 - Overview
The ImmunoMark Summit 2026, conceptualized and curated by Convolign Business Consulting, will unite global pioneers and innovators in Immuno-Oncology (IO) and biomarker discovery, offering a strategic forum to drive the next generation of biomarkers critical to the success of IO therapies. As immunotherapies continue to reshape the landscape of cancer care, the identification and validation of robust, clinically relevant biomarkers are becoming central to the realization of precision medicine.
This two-day summit will explore cutting-edge advances in IO science, novel biomarker identification, companion diagnostics, translational research, clinical validation, and evolving regulatory frameworks. With two dedicated parallel tracks—Next-Gen Immuno-Oncology (NGIO) and Biomarker & Companion Diagnostics—attendees will gain deep, actionable insights, forge meaningful partnerships, and accelerate the path from discovery to delivery.
Designed to be dynamic and interactive, the event features expert-led panel discussions, real-world case studies, and one-to-one networking opportunities. Whether you're involved in academia, clinical research, pharma, diagnostics, or regulatory affairs, ImmunoMark Summit 2026 is the essential platform for stakeholders dedicated to advancing biomarker-driven solutions and transforming the future of cancer treatment.
Join us at London, UK to connect with thought leaders, gain actionable insights, and contribute to the global pioneers and innovators in Immuno-Oncology (IO) and biomarker discovery.
Key Highlights
Stream 1 - Immuno Oncology
- Next-Gen Immuno-Oncology
- Emerging IO therapeutic approaches beyond PD-1/PD-L1
- TCR-T and CAR-T Cell Therapy advancements
- Overcoming IO resistance mechanisms
- Tumor Microenvironment (TME) modulation
- Personalized cancer vaccines and neoantigens
Stream 2 - Biomarker & Companion Diagostics
- Biomarker & Companion Diagnostics
- Breakthroughs in predictive, diagnostic, and prognostic biomarkers
- Liquid biopsy technologies for real-time monitoring
- Companion diagnostics development and commercialization strategies
- Role of single-cell and multi-omics technologies in biomarker discovery
- Regulatory trends and reimbursement insights for biomarkers and CDx
0
Industry Expert Speakers
0
Attendees Across Pharmaceutical & Biotech Companies, Emerging Biotech Firms, Academic & Research Institutions
What makes our Program Unique?
Two parallel, focused streams designed to cater to diverse professional interests—one concentrating on cutting-edge Immuno-Oncology innovations and the other on breakthroughs in Biomarker and Companion Diagnostics—offering participants the flexibility to tailor their learning journey.
A rich blend of scientific advancements, clinical case studies, and commercial strategies ensures that attendees gain a comprehensive view of both theoretical innovations and their practical, real-world applications.
Facilitated one-to-one networking opportunities and strategic collaborations enable meaningful connections with key stakeholders across the pharma, biotech, diagnostics, and research communities.
Interactive panel discussions featuring global experts that tackle real-world clinical and commercial challenges, fostering open dialogue and knowledge exchange.
Special sessions focused on translational medicine and evolving regulatory frameworks, helping attendees bridge the gap between bench and bedside while staying ahead of compliance trends.
Conclude Day 1 with a vibrant Drinks Reception and Gala Dinner, providing a relaxed atmosphere to strengthen professional relationships and engage with peers informally.
Join 300+ industry-focused attendees, ensuring an unparalleled networking experience and a critical mass of decision-makers, innovators, and influencers from across the immuno-oncology and biomarker ecosystem.
Expert Speakers
Immuno-Oncology
Biomarker and Companion Diagnostics
Nina Garrett
CTO
Abingdon Health
Sponsors & Partners
Platinum Sponsors
Gold Sponsor
Silver Sponsors
Exhibitors
Visiting Partners
Media Partners
Delegates
Who Should Attend?
Pharmaceutical & Biotech Companies:
- Drug Discovery Scientists
- Clinical Development Leads
- Translational Medicine Experts
- Regulatory Affairs Professionals
- Business Development Executives
Emerging Biotech Firms:
- Startup Founders and CEOs
- R&D Scientists
- Investor Relations Officers
- Clinical Operations Managers
Academic & Research Institutions:
- Principal Investigators
- Postdoctoral Researchers
- Graduate Students
- Tech Transfer Office Representatives
Other Key Attendees:
- CROs & CDMOs
- Regulatory Bodies
- Venture Capitalists
Key Departments
Research & Development (R&D):
- Preclinical Research
- Translational Research
- Biomarker Discovery
- Target Identification & Validation
Clinical Development:
- Clinical Operations
- Medical Affairs
- Clinical Pharmacology
- Early/Translational Clinical Programs
Translational Medicine:
- Clinical Biomarker Teams
- Genomics/Proteomics Analysis
- Companion Diagnostics Development
Regulatory Affairs:
- Regulatory Science
- Companion Diagnostic Submissions
- Health Authority Engagement
Business Development & Strategy:
- Licensing & Partnerships
- Corporate Strategy
- Innovation Scouting
Data Science & Bioinformatics:
- Multi-omics Data Analysis
- AI/ML in Biomarker Discovery
- Real-World Evidence Integration
Why Attend?
Discover the latest innovations in Immuno-Oncology therapies and biomarker science, including novel targets, therapeutic strategies, and emerging technologies that are shaping the future of precision medicine.
Gain actionable insights from world-renowned researchers, pharmaceutical leaders, diagnostic experts, and regulatory authorities, offering a 360° perspective on scientific, clinical, and commercial developments.
Engage with a diverse and influential community of professionals, including scientists, clinicians, diagnostic developers, and business leaders—ideal for building new collaborations, partnerships, and career opportunities.
Explore real-world strategies for biomarker validation, clinical trial design, and regulatory approval, empowering attendees with practical tools to drive innovation from the lab to the clinic.
Participate in dynamic and interactive formats, including thought-provoking panel discussions, solution-focused case studies, and in-depth presentations that go beyond theory to tackle real challenges and success stories in the field.
